Inari Medical (NASDAQ: NARI)+ today announced a definitive agreement to purchase LimFlow Medical for up to $415 million. The deal comes just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough system to treat chronic limb-threatening ischemia (CLTI).
Inari Medical plans to buy LimFlow Medical for up to $415M
